Cullinan Therapeutics (CGEM) Metrics: History & Chart

Cullinan Therapeutics, Inc.(CGEM)

Biotechnology · Cambridge, MA

$16.63+0.59 (+3.70%)

Delayed quote: Oct 6, 2026, 9:35 AM EDT

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cambridge, MA

109 employees

cullinantherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Nadim Ahmed

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+7.29%
30D Total Return	-27.39%
YTD Total Return	+54.98%
1Y Total Return	+171.86%
3Y Total Return	+85.84%
5Y Total Return	-32.20%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+54.98%
2025	-15.02%
2024	+19.53%
2023	-3.41%
2022	-31.63%
2021	N/A

CAGR TTM	+170.57%
CAGR 3Y	+22.94%
CAGR 5Y	-7.48%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	8.43
PE Ratio Avg TTM	5.13
PE Ratio Avg 3Y	5.13
Current VS TTM Avg	+64.24%
Current VS 3Y Avg	+64.24%
Current VS 5Y Avg	+64.24%

All Metrics

CGEM Valuation Metrics

CGEM Stock Price Metrics

CGEM Dividend Metrics

CGEM Growth Rate Metrics

CGEM Discounted Cash Flow Metrics

CGEM Returns By Period

CGEM Yearly Returns

CGEM Average Annual Returns By Period (CAGR)

CGEM Revenue Metrics

CGEM PE Ratio Metrics

CGEM PS Ratio Metrics

CGEM PB Ratio Metrics

CGEM Price to Free Cash Flow Ratio Metrics

CGEM Debt to Equity Ratio Metrics

CGEM PEG Ratio Metrics

CGEM FCF Yield

CGEM Earnings Yield

CGEM EBITDA Yield

CGEM OCF Yield

CGEM EV/EBIT Ratio Metrics

CGEM EV/EBITDA Ratio Metrics

CGEM EV/Assets Ratio Metrics

CGEM EV/Sales Ratio Metrics

CGEM Current Ratio Metrics

CGEM Quick Ratio Metrics

CGEM ROIC Metrics

CGEM Return on Assets Metrics

CGEM Return on Equity Metrics

CGEM Net Profit Margin Metrics

CGEM Gross Profit Margin Metrics

CGEM Tax Rate Metrics

PS Ratio	25.07
PS Ratio Avg TTM	45.53
PS Ratio Avg 3Y	45.53
Current VS TTM Avg	-44.94%
Current VS 3Y Avg	-44.94%
Current VS 5Y Avg	-44.94%

PB Ratio	3.07
PB Ratio Avg TTM	2.19
PB Ratio Avg 3Y	1.43
Current VS TTM Avg	+40.44%
Current VS 3Y Avg	+114.24%
Current VS 5Y Avg	+143.48%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.01
Debt/Equity Ratio Avg 3Y	0.01
Current VS TTM Avg	+27.57%
Current VS 3Y Avg	+3.57%
Current VS 5Y Avg	+13.77%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	11.86%
Earnings Yield Avg TTM	18.60%
Earnings Yield Avg 3Y	18.60%
Current VS TTM Avg	-36.24%
Current VS 3Y Avg	-36.24%
Current VS 5Y Avg	-36.24%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	2.65
Ev/Ebit Ratio Avg TTM	2.07
Ev/Ebit Ratio Avg 3Y	2.07
Current VS TTM Avg	+28.24%
Current VS 3Y Avg	+28.24%
Current VS 5Y Avg	+28.24%

Ev/Ebitda Ratio	2.64
Ev/Ebitda Ratio Avg TTM	2.06
Ev/Ebitda Ratio Avg 3Y	2.06
Current VS TTM Avg	+27.86%
Current VS 3Y Avg	+27.86%
Current VS 5Y Avg	+27.86%

Ev/Assets Ratio	2.50
Ev/Assets Ratio Avg TTM	1.79
Ev/Assets Ratio Avg 3Y	1.18
Current VS TTM Avg	+39.33%
Current VS 3Y Avg	+111.63%
Current VS 5Y Avg	+143.14%

Ev/Sales Ratio	21.91
Ev/Sales Ratio Avg TTM	38.08
Ev/Sales Ratio Avg 3Y	38.08
Current VS TTM Avg	-42.46%
Current VS 3Y Avg	-42.46%
Current VS 5Y Avg	-42.46%

Current Ratio	8.42
Current Ratio Avg TTM	9.85
Current Ratio Avg 3Y	16.21
Current VS TTM Avg	-14.51%
Current VS 3Y Avg	-48.08%
Current VS 5Y Avg	-53.80%

Quick Ratio	8.42
Quick Ratio Avg TTM	9.85
Quick Ratio Avg 3Y	16.21
Current VS TTM Avg	-14.51%
Current VS 3Y Avg	-48.08%
Current VS 5Y Avg	-53.80%

ROIC	(68.64%)
ROIC Avg 3Y	(44.21%)
ROIC Avg 5Y	(27.34%)
Current VS 3Y Avg	-55.24%
Current VS 5Y Avg	-151.00%
Current VS 10Y Avg	-159.67%

ROA	(56.27%)
ROA Avg TTM	(12.46%)
ROA Avg 3Y	(9.08%)
Current VS TTM Avg	-351.51%
Current VS 3Y Avg	-519.95%
Current VS 5Y Avg	-624.02%

ROE	(63.62%)
ROE Avg TTM	(53.56%)
ROE Avg 3Y	(38.43%)
Current VS TTM Avg	-18.77%
Current VS 3Y Avg	-65.54%
Current VS 5Y Avg	-109.81%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	27.51%
Tax Rate Avg 3Y	13.76%
Tax Rate Avg 5Y	13.76%
Current VS 3Y Avg	+100.00%
Current VS 5Y Avg	+100.00%
Current VS 10Y Avg	+100.00%